COVID-19 Patients With Pulmonary Hypertension Hospitalized in the United States During the Early Pandemic: Analysis of In-Hospital Mortality, Clinical Outcomes, and Racial Disparities

Majeed, Harris; Cannon, Harmon R.; Raj, Kavin; Nasrullah, Adeel; Majeed, Safwan; Gangu, Karthik; Farooq, Asif; Sheikh, Abu Baker

doi:10.1016/j.cpcardiol.2023.101933

Cited by 3 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There have been reports of pulmonary hypertension as a complication of SARS-CoV-2 infection, but most have concerned adult cases ( 3 ). This report describes the case of a pediatric patient who was admitted to hospital in the acute phase of SARS-CoV-2 infection with fever, respiratory distress, and impaired consciousness and was diagnosed as having pulmonary hypertension as a complication of SARS-CoV-2 infection.…”

Section: Introductionmentioning

confidence: 99%

A case report of a child with pulmonary hypertension associated with SARS-CoV-2 infection

Okunushi,

Kobayashi,

Yoh

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

We encountered a pediatric case of pulmonary hypertension triggered by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. A 14-year-old girl was brought to the emergency department of our hospital with fever, respiratory distress, and impaired consciousness. She tested positive for SARS-CoV-2 upon a polymerase chain reaction examination and had prolonged hypoxemia without pneumonia. An echocardiography revealed elevated right ventricular pressure. She was diagnosed with pilocytic astrocytoma at the age of 10 years and underwent a resection of a pituitary tumor. Hormone replacement therapy was administered postoperatively, but her growth hormones were not activated because of concerns about tumor recurrence. Echocardiography at the age of 13 years showed normal right ventricular pressure. On admission, she had an abnormal liver function, elevated liver fibrosis markers, a decreased platelet count, and hepatosplenomegaly, suggesting pulmonary and portal hypertension. The diagnosis was pulmonary hypertension associated with SARS-CoV-2 infection. The mechanism of the pulmonary hypertension was thought to be portal hypertension owing to growth hormone deficiency and SARS-CoV-2 infection. The patient's symptoms improved with oxygenation and bed rest without additional targeted pulmonary hypertension therapy, and her right ventricular pressure decreased. This case demonstrates that a pediatric patient with subclinical pulmonary hypertension may develop pulmonary hypertension triggered by SARS-CoV-2 infection.

show abstract

Section: Introductionmentioning

confidence: 99%

A case report of a child with pulmonary hypertension associated with SARS-CoV-2 infection

Okunushi,

Kobayashi,

Yoh

et al. 2024

Front. Pediatr.

View full text Add to dashboard Cite

show abstract

Clinical impact of pulmonary arterial hypertension on SARS-CoV-2 outcomes: U.S. pre-vaccination analysis

Tamimi,

Ejikeme,

Nisar

et al. 2024

Current Problems in Cardiology

View full text Add to dashboard Cite

Pulmonary hypertension-related deaths in patients with acute pulmonary embolism in the United States, 2003 to 2020

Zuin,

Badagliacca,

Harder

et al. 2024

Vasc Med

View full text Add to dashboard Cite

Background: Data regarding the mortality trends in pulmonary embolism (PE)-related mortality in patients with concomitant pulmonary hypertension (PH) are lacking. We assessed the trends in PE-related mortality in patients with concomitant PH in the United States (US) over the past 2 decades and during the first year of the COVID-19 pandemic using data from the Centers for Disease Control and Prevention’s (CDC) Wide-ranging ONline Data for Epidemiologic Research (WONDER) dataset. Methods: Mortality data were retrieved from the publicly available CDC WONDER mortality dataset from 2003 to 2020. Age-adjusted mortality rates (AAMRs), per 100,000 population, were assessed using Joinpoint regression modelling and expressed as estimated average annual percentage change (AAPC) with relative 95% CIs and stratified by urbanicity, sex, age, and race/ethnicity. Results: Over the study period, the AAMR for PE/PH-related mortality linearly increased (AAPC: +4.3% [95% CI: 3.7 to 4.9], p < 0.001) without sex differences. The AAMR increase was more pronounced in White individuals (AAPC: +4.8% [95% CI: 4.1 to 5.5], p < 0.001) and in subjects living in rural areas (AAPC: +5.1% [95% CI: 3.8 to 6.4], p < 0.001) compared to those living in urban areas. During the first year of the COVID-19 pandemic there was a significant excess in PE/PH-related mortality among women, older than 65 years and living in rural areas. Conclusions: The rate of PE/PH-related mortality in the US is increasing. Although the early diagnosis of PH in patients with acute PE has become easier with improved diagnostic modalities, the mortality rate of these patients remains high.

show abstract

COVID-19 Patients With Pulmonary Hypertension Hospitalized in the United States During the Early Pandemic: Analysis of In-Hospital Mortality, Clinical Outcomes, and Racial Disparities

Cited by 3 publications

References 19 publications

A case report of a child with pulmonary hypertension associated with SARS-CoV-2 infection

A case report of a child with pulmonary hypertension associated with SARS-CoV-2 infection

Clinical impact of pulmonary arterial hypertension on SARS-CoV-2 outcomes: U.S. pre-vaccination analysis

Pulmonary hypertension-related deaths in patients with acute pulmonary embolism in the United States, 2003 to 2020

Contact Info

Product

Resources

About